Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 QT/QTc Evaluation of JTE-051 in Healthy Adults
jRCT2071250099Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JTE-051 in Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS) (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Central tendency of QTcF. Started Jan 2026; status: completed.
02
Drugs
JTE-051
03
Conditions
Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS)
Beyond the preview
Go deeper on jRCT2071250099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250099.